4th Antigen-Specific Immune Tolerance Drug Development

The 4th Antigen-Specific Immune Tolerance Drug Development is dedicated to safe and effective antigen-specific immune tolerance therapies.

The 4th Antigen-Specific Immune Tolerance Drug Development covers topics such as:

• Analyzing the Scope & Strategies to Antigen-Specific Immune Tolerance
• Dynamics of Underlying Causes & Current Understandings of Autoimmunity
• Improving the Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies
• Identification, Validation & Targeting of Specific Antigens for Immune Tolerance Therapies
• Optimizing Clinical Development & Paving the Future of Antigen-Specific Immune Tolerance Therapies
• Surging Translational Potentials of Pre-Clinical Antigen-Specific Therapies
• Commercialization: Future Proofing Immune Tolerance Therapies for Patients

The 4th Antigen-Specific Immune Tolerance Drug Development will be held on 27-28 Jan 2021.